cardiacare

Company Profile: CardiaCare

Overview

CardiaCare is a cutting-edge digital therapeutic company based in HaMerkaz, specializing in the development of a first-of-its-kind closed-loop wearable device for the non-invasive treatment of atrial fibrillation (AFib) and other Central Nervous System (CNS) related clinical symptoms. The company's technology facilitates continuous monitoring and incorporates AI-driven alerts to enable comprehensive remote patient management and personalized therapy. By utilizing peripheral neuromodulation technology, CardiaCare delivers cardiovascular anti-arrhythmic responses, offering significant improvements for AFib patients.

Key Offerings

CardiaCare’s flagship product is a non-invasive wearable therapeutic device designed primarily for home use, allowing for the remote monitoring and treatment of atrial fibrillation. The device recently completed a First-In-Human (FIH) clinical trial at the Chaim Sheba Medical Center, showcasing its effective safety profile and success in reducing arrhythmia occurrences and the long-term recurrence of AFib after hospital discharge.

Achievements and Industry Standing

CardiaCare is esteemed in the MedTech community, having been recognized as a top 50 startup in the 2022 cohort of the world's largest MedTech accelerator, the MedTech Innovator programs. The company received the First Prize at the 2019 Innovation in Cardiovascular Interventions Technology Parade in Tel Aviv, emphasizing its pivotal role and excellence in cardiac care innovation.

Strategic Partnerships

CardiaCare has strategically partnered with Dr. Reddy’s Laboratories through a licensing agreement, emphasizing significant external validation of its pioneering technology. This collaboration is poised to bolster market penetration and expedite the adoption of neuromodulation-based atrial fibrillation treatments.

Leadership Team

• Amos Ziv, CEO: An experienced entrepreneur in cardiovascular support, previously led the Integrative Medicine Research Unit at Assaf Harofeh Medical Centre.

• Tsahi Holand, CTO: A senior engineer with over a decade of expertise in R&D, specializing in signal processing and embedded software applications.

• Eial Ferencz, Full-Stack Developer: Holds extensive experience in architecture design for servers, websites, and applications.

• Adi Benari, Clinical Trials Manager: Boasts over eight years in clinical trials management, with a focus on global execution and medical device sector monitoring.

• Tikva Leybovitch, Clinical Research Associate: Expert in overseeing clinical trials, ensuring regulatory compliance and safety.

Advisory Board

• Ken Nelson, Chairman: With leading roles at Biotronik’s Digital Health, Diagnostics, and Monitoring divisions, Nelson brings valuable industry experience, including multiple successful exits in the cardiac field.

• Prof. Vivek Y. Reddy, Advisor: A renowned director of Cardiac Arrhythmia Services at Mount Sinai Hospital, offering critical clinical insights.

• Ron Sacher, Adviser: A seasoned veteran in medical device executive positions, notable for facilitating successful mergers and acquisitions such as leading SI Therapies to successful exits.

Research and Development

CardiaCare is actively engaged in research and development, perpetually refining its wearable therapeutic platform to enhance cardiac patient outcomes. Despite the device's ongoing regulatory evaluation, it promises revolutionary yet experimental solutions for cardiac and CNS-related treatments. CardiaCare emphasizes innovation, leveraging interdisciplinary expertise to maintain leadership in neuromodulation therapy.

Competitor Profile

Overview

CardiaCare operates within a competitive landscape focused on innovating solutions for Atrial Fibrillation, aiming to reduce episode frequency and enhance patient quality of life. Its competitors include AliveCor, iRhythm Technologies, Inc., CardioNet, Inc., Apple, and Imperative Care, each offering varying solutions in digital health and cardiology.

Key Competitors

AliveCor

• Founded: 2010

• Location: Mountain View, California

• Specialties: Mobile ECG devices with AI-enabled technology.

• Product Highlights: KardiaMobile device for detecting Atrial Fibrillation and other cardiac irregularities.

• Market Position: A leader in personal ECG solutions, aligning with digital healthcare integration and remote patient monitoring.

• Recent Activity: Initiated Series F funding in 2022 supported by major investors like GE Healthcare.

iRhythm Technologies, Inc.

• Employees: Approximately 2,000

• Specialties: Focusing on cardiac monitoring and arrhythmia detection.

• Products: Zio ECG monitors utilizing FDA-cleared AI technology.

• Market Insight: Leverages advanced biosensors and maintains a comprehensive database of heartbeat data.

• Innovation Strategy: Emphasizes precision, accessibility, and global healthcare innovation.

CardioNet, Inc.

• Focus: Pioneering Mobile Cardiac Telemetry (MCOT™) for real-time ECG monitoring.

• Competitive Edge: Early market entry with regulatory successes, vigorously protecting IP through key legal actions.

Apple

• Sector: Integrating health technologies across consumer products.

• Offerings: Apple Watch ECG applications, Health Records on iPhone.

• Strategy: Merging consumer electronics with healthcare functionalities for personalized care.

Imperative Care

• Focus: Addressing stroke and vascular disease, expanding medical technology access through digital health and robotics.

• Innovations: Developing solutions for ischemic and hemorrhagic strokes, focusing on underserved medical areas.

Strategic Insights

CardiaCare competes with a mix of specialized medical tech firms and tech giants. Companies like AliveCor leverage AI and consumer electronics, while iRhythm fosters precise arrhythmia detection using biosensors. CardiaCare’s emphasis on atrial fibrillation positions it well for success amid a landscape favoring innovation, strategic partnerships, and regulatory prowess.